World News – CA – ASX Stock of the Day: Immutep (ASX: IMM) Shares Up 60% On Test News


. .

For a limited time, The Motley Fool Australia is releasing an urgent new investment report detailing our 5 favorite stocks for investors over 50. Every company has strong growth prospects for the next 3 to 5 years and most importantly, each pays a generous (and fully stamped) dividend! So if you want to get your finances in order and are in or about to retire, you’ve come to the right place!

ASX 200 | A B C D E F G H I J L M N O P Q R S T U V W X

The Motley Fool Australia »Stock Market News» ASX Stock of the Day: Immutep (ASX: IMM) shares rise 60% on test news

Sebastian Bowen | 10. December 2020, 5:15 pm | More about: AVH IMM RMD

Immutep Ltd (ASX: IMM) share price is on fire today, rising nearly 60%. Immutep stock closed at 28 cents a share yesterday afternoon but opened at 45 cents this morning before rising to a high of 54 cents. The price of the Immutep share has cooled a bit since then, but is still trading at 60. 7% higher at 45 cents per share at the time of writing.

Today’s price action also marks a new 52-week high for the company, which hit its previous high back in February before the stock fell more than 75% after the coronavirus-induced market crash in March. Even so, today’s moves mean Immutep shares are up more than 320% from their late March lows.

So what is this company? And why is the price of Immutep shares exploding so dramatically today?

Immutep is a biopharmaceutical company founded in 2001. It is a dual-listing company listed on the ASX under the IMM ticker code and on the US Nasdaq stock exchange as Immutep ADS (NASDAQ: IMMP). .

Companies are often duplicated to attract more investor capital, especially in the US where the stock markets are by far the most capitalized in the world. It’s also not the only publicly traded stock between Australia and the US in the medical / biopharmaceutical space. Well-known ASX examples are Resmed Inc (ASX: RMD) and Avita Therapeutics Inc (ASX: AVH). .

Immutep describes itself as « a leader in the development of immunotherapy for cancer and autoimmune diseases ». . It is said that his goal is « to use and strengthen the strength of the body’s immune system through therapeutic interventions for the benefit of the patient’s health ». .

His specialty is the understanding and development of therapeutics that modulate the lymphocyte activation gene-3, or « LAG-3 » as the company calls it. LAG-3 appears to be a « cell surface molecule that plays an important role in the regulation of T cells ». . T cells are a type of white blood cell that is an essential part of the body’s immune system. They help the body identify and eliminate foreign pathogens, diseases, and other threats.

Immutep reportedly has 1 pre-clinical and 3 clinical LAG-3 product candidates in development, including two antibodies to modulate immune responses in autoimmunity and cancer. It is apparently a partnership with global pharmaceutical giants Novartis and GlaxoSmithKline.

Immutep stock price appears to be responding to some of the ASX releases the company announced this morning before the market opened.

First, Immutep reported that it had a « statistically significant » survival benefit for patients in an ongoing study. The company notes that these benefits mark the first time an antigen-presenting cell activator has an overall survival benefit in a randomized setting in patients with metastatic breast cancer known to be insensitive to immune checkpoint inhibitor therapy having.

However, the company states that the data collection has not yet been completed and a final report on the matter will not be available until mid-2021. Even so, these data appear to show that the treatment treated resulted in 7. 1 month and 9. 4 month survival benefits for 2 patient groups.

The second announcement by Immutep is that the Chinese partner company EOC Pharma is starting a new clinical phase II study for up to 152 metastatic breast cancer patients in China. The aim of this study is to evaluate the “efficacy and safety of eftilagimod alpha” in conjunction with chemotherapy treatments for these cancer patients. Eftilagimod alpha (efti), also called LAG-3Ig or IMP321, is, according to the company, a « first class activator for antigen-presenting cells (APC) ». .

EOC Pharma has reached an agreement with Immutep to « make further milestone payments to the company if efti reaches certain development milestones as well as unspecified license fees for sales and also has to finance efti’s Chinese development ». .

When investment expert Scott Phillips has a stock tip, it can be worth listening. After all, the Motley Fool Share Advisor’s flagship newsletter, which it has operated for more than eight years, has offered thousands of paying members stock choices that have doubled, tripled, or even more. *

Scott just revealed what he thinks are the top five ASX stocks investors can buy right now. These stocks trade at dirt cheap prices, and Scott thinks they are great buys right now.

Sebastian Bowen has no position in any of the stocks mentioned. Motley Fool Australia’s parent company, Motley Fool Holdings Inc. . owns shares in Avita Medical Limited. The Motley Fool Australia has Avita Medical Limited and ResMed Inc. Recommended. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). . Authorized by Bruce Jackson.

In this FREE SHARE REPORT, Scott Phillips just revealed what he thinks are the 3 ASX stocks for the post-COVID world that investors should buy now while they still can.

. Fools Ecap. Fool-ecap-id-19. Fool-Ecap-Type-Vanilla {background: # fff7c4;} aside section . Fool-ecap-id-19. Fool-ecap-type-vanilla h3 {font size: 1. 6em;} p. ecap disclaimer {font size: 0. 6em! Important;} div. Fools Ecap. Narr-Ecap-ID-19-Form {position: relative; Text alignment: center; Edge: . 2em 1em;}. Fools Ecap. Fool-Ecap-ID-19 p. ecap disclaimer {margin-left: 0px;} . Fools Ecap. Fool-Ecap-ID-19 p. via email {bottom margin: 0px; Text alignment: middle;} div. Fools Ecap. Narr-Ecap-ID-19 p {color: # 464646;}. Fools Ecap Type Vanilla. Narr-Ecap-ID-19 h3 {color: # 404040; Advertisement: Block! important;}. Fools Ecap Type Vanilla. Fool-ecap-id-19 . ecap disclaimer {color: # 484848! important;}. Fool-ecap-id-19. Fool Ecap Type Vanilla h3. Title {display: none! important;} . Fools Ecap. Fool-ecap-id-19. Fool-ecap-type-vanilla {bottom-edge: 10px;}. Fools Ecap Type Vanilla. Narr-Ecap-ID-19 input [type = « send »] {margin: . 5rem 0 . 5rem! Important;}. Fools Ecap. fool-ecap-id-19 img {display: inline;}

By clicking this button you agree to our terms of use and privacy policy. We only use your email address to keep you informed about updates to our website and about other products and services that we think may interest you. You can unsubscribe at any time. Further information can be found in our Financial Services Guide (FSG).

This service only provides general, not personalized, financial advice and has not taken your personal circumstances into account. The Motley Fool Australia operates under AFSL 400691. You can find more information in our Financial Services Guide. Please remember that investments can go up and down. Past performance is not necessarily an indication of future returns. The Motley Fool Australia does not guarantee any performance or return on any investment.

Immutep, ASX, share, ASX: IMM, metastatic breast cancer, NASDAQ: IMMP, eftilagimod alpha

World News – CA – ASX share of the day: Immutep (ASX: IMM) shares in test news up 60%
. . Related title :
ASX share of the day: Immutep shares (ASX: IMM) rise 60% in study news
Immutep Updates AIPAC Breast Cancer Study and Announces New Study
Closing Bell: TodaySSSEANDCHARs largest small-cap mover at the ASX
Immutep& (ASX: IMM) breast cancer therapy is slated for Phase 2 trial in China
Immutep shares rise 57% thanks to two big announcements
The Chinese partner of Immutep& starts a clinical phase II study for patients with metastatic breast cancer
Immutep&’s Chinese partner EOC Pharma starts the phase II study on metastatic breast cancer
Immutep 72% after breast cancer study shows promising survival data
Immutep reports statistically significant survival benefit for important patient groups in the ongoing phase IIb AIPAC study . . .
Immutep – Overall Survival Data from AIPAC Breast Cancer Study of ph IIb


Donnez votre avis et abonnez-vous pour plus d’infos

Vidéo du jour: